Archer Materials Technology ASX Announcement (ASX: AXE) 19 November 2026 Archer completes beta prototype of Biosensor; progressing towards clinical trials Highlights • Archer has advanced the engineering and development of its Biosensor beta prototype • The Beta prototype translates positive...
Archer completes beta prototype of Biosensor
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Archer Materials Limited has announced the completion of its Biosensor beta prototype, marking a significant milestone in its development of point-of-care blood-testing technology. The beta prototype is ready for external testing and validation, moving towards clinical trials and initial manufacturing development. Archer is engaging with tier-one clinical partners to support external validation and is focusing on lithium testing as the initial application. The CEO highlighted the device's integration of complex workflows into a user-friendly format aimed at improving patient care.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Archer Materials Limited on 6ix
In the deck
Story so far
Earlier from Archer Materials
- Archer appoints global technology leader to drive quantum
- Quarterly Activities/Appendix 4C Cash Flow Report
- Change of registry address notification
- Notice of Annual General Meeting/Proxy Form
- Notification regarding unquoted securities - AXE
Later from Archer Materials
All Archer Materials news releasesFollow Archer Materials into a list and get an email when it puts out news.
Follow Archer Materials